| Adjuvant trastuzumab in HER2-positive breast cancer D Slamon, W Eiermann, N Robert, T Pienkowski, M Martin, M Press, ... New England journal of medicine 365 (14), 1273-1283, 2011 | 3311 | 2011 |
| Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised … E Pujade-Lauraine, JA Ledermann, F Selle, V Gebski, RT Penson, ... The lancet oncology 18 (9), 1274-1284, 2017 | 1779 | 2017 |
| Whole–genome characterization of chemoresistant ovarian cancer AM Patch, EL Christie, D Etemadmoghadam, DW Garsed, J George, ... Nature 521 (7553), 489-494, 2015 | 1580 | 2015 |
| Cervical cancer: a global health crisis W Small Jr, MA Bacon, A Bajaj, LT Chuang, BJ Fisher, MM Harkenrider, ... Cancer 123 (13), 2404-2412, 2017 | 1285 | 2017 |
| Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre … SM de Boer, ME Powell, L Mileshkin, D Katsaros, P Bessette, ... The lancet oncology 19 (3), 295-309, 2018 | 616 | 2018 |
| Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy A León-Castillo, SM De Boer, ME Powell, LR Mileshkin, HJ Mackay, ... Journal of Clinical Oncology 38 (29), 3388-3397, 2020 | 606 | 2020 |
| Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis S Moran, A Martínez-Cardús, S Sayols, E Musulén, C Balañá, ... The Lancet Oncology 17 (10), 1386-1395, 2016 | 477 | 2016 |
| Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative E Stelloo, T Bosse, RA Nout, HJ MacKay, DN Church, HW Nijman, ... Modern pathology 28 (6), 836-844, 2015 | 466 | 2015 |
| Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a … SM de Boer, ME Powell, L Mileshkin, D Katsaros, P Bessette, ... The lancet oncology 20 (9), 1273-1285, 2019 | 434 | 2019 |
| Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double … A Poveda, A Floquet, JA Ledermann, R Asher, RT Penson, AM Oza, ... The Lancet Oncology 22 (5), 620-631, 2021 | 340 | 2021 |
| Pembrolizumab in patients with microsatellite instability–high advanced endometrial cancer: results from the KEYNOTE-158 study DM O'Malley, GM Bariani, PA Cassier, A Marabelle, AR Hansen, ... Journal of Clinical Oncology 40 (7), 752-761, 2022 | 333 | 2022 |
| Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring L Mileshkin, R Stark, B Day, JF Seymour, JB Zeldis, HM Prince Journal of Clinical Oncology 24 (27), 4507-4514, 2006 | 267 | 2006 |
| Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors JR Infante, DR Camidge, LR Mileshkin, EX Chen, RJ Hicks, D Rischin, ... Journal of Clinical Oncology 30 (13), 1527-1533, 2012 | 255 | 2012 |
| Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre … SM de Boer, ME Powell, L Mileshkin, D Katsaros, P Bessette, ... The Lancet Oncology 17 (8), 1114-1126, 2016 | 195 | 2016 |
| Low physical activity levels and functional decline in individuals with lung cancer CL Granger, CF McDonald, L Irving, RA Clark, K Gough, A Murnane, ... Lung Cancer 83 (2), 292-299, 2014 | 189 | 2014 |
| The molecular origin and taxonomy of mucinous ovarian carcinoma D Cheasley, MJ Wakefield, GL Ryland, PE Allan, K Alsop, ... Nature communications 10 (1), 3935, 2019 | 156 | 2019 |
| Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age L Mileshkin, JJ Biagi, P Mitchell, C Underhill, A Grigg, R Bell, ... Blood 102 (1), 69-77, 2003 | 148 | 2003 |
| Selective targeting of cyclin E1-amplified high-grade serous ovarian cancer by cyclin-dependent kinase 2 and AKT inhibition G Au-Yeung, F Lang, WJ Azar, C Mitchell, KE Jarman, K Lackovic, D Aziz, ... Clinical Cancer Research 23 (7), 1862-1874, 2017 | 143 | 2017 |
| Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for … FA Eggink, IC Van Gool, A Leary, PM Pollock, EJ Crosbie, L Mileshkin, ... Oncoimmunology 6 (2), e1264565, 2017 | 140 | 2017 |
| Gynecologic Cancer InterGroup (GCIG) consensus review for small cell carcinoma of the cervix T Satoh, Y Takei, I Treilleux, M Devouassoux-Shisheboran, J Ledermann, ... International Journal of Gynecologic Cancer 24 (Supp 3), 2014 | 139 | 2014 |
